BOLD

Boundless Bio, Inc. went public on March 28, 2024, listing on NASDAQ, and its stock has trended up by 24.39% over the past six months. In December 2025, the company participated in the Piper Sandler 37th Annual Healthcare Conference. In January 2026, the FDA accepted the IND application for BBI-940, allowing the initiation of the Phase 1 KOMODO-1 clinical trial in February 2026, accompanied by the discontinuation of the POTENTIATE trial. In February 2026, the company participated in the Guggenheim Emerging Outlook: Biotech Summit 2026. In March 2026, Boundless Bio reported its Fourth Quarter and Full Year 2025 financial results and business highlights and announced an upcoming presentation of its oral Kinesin degrader program at the American Association for Cancer Research Annual Meeting 2026, with an analyst price target increase of 33.33% to $4.08. In April 2026, the company presented preclinical breast cancer data from its oral Kinesin degrader program (BBI-940) at the 2026 AACR Annual Meeting. On May 8, 2026, Boundless Bio reported its First Quarter 2026 financial results and business highlights, showing a narrowed net loss and reduced R&D and G&A expenses, highlighting ongoing enrollment in the KOMODO-1 trial and a cash runway expected to fund operations into the second half of 2028.